CVS Health Corp Earnings - Q3 2026 Analysis & Highlights
CVS Health reported Q3 2026 growth across all operating segments, raised its 2026 outlook, and announced plans to separate into two public companies, while highlighting elevated healthcare cost trends, continued Medicare recovery, and expected 2027 growth.
Key financial results
Revenue exceeded $108 billion in Q3; the company did not state a year-over-year revenue growth rate in the call.
Adjusted operating income was nearly $4.2 billion, with management reporting earnings growth across all operating segments.
Adjusted EPS was $2.09, up more than 30% year over year.
Cash flow from operations was approximately $4.7 billion in Q3 and $15.3 billion year to date.
Business segment results
Health Care Benefits: Adjusted operating income was approximately $900 million, nearly $600 million above the prior-year quarter; the medical benefit ratio was 91.3%, an improvement of approximately 150 basis points year over year. Management attributed the performance primarily to improved Medicare results, including strong medical cost management and disciplined pricing.
Health Services: Adjusted operating income was $2.1 billion, up nearly 3% year over year, primarily reflecting improved purchasing economics and pharmacy drug mix, partly offset by continued pharmacy client price improvements. Pharmacy services, including 340B and rebate guarantees, and healthcare delivery performed in line with expectations.
Pharmacy & Consumer Wellness: Adjusted operating income exceeded $1.6 billion, up more than 10% year over year, driven mainly by core pharmacy strength; same-store prescription volumes increased nearly 4%. Business investments and consumer dynamics partly offset the growth.
Capital allocation
CVS Health returned nearly $2.6 billion to shareholders through dividends in 2026 through Q3.
The company ended the quarter with nearly $6 billion of cash at the parent and unrestricted subsidiaries and said it had achieved its leverage goal ahead of schedule.
Management expects to resume the share repurchase program in Q4 2026; the CFO said the company’s improved balance sheet and cash generation support capital deployment.
Management expects each company after separation to have a solid investment-grade capital structure and strong free cash flow, supporting capital allocation tailored to each company’s strategy.
The call did not provide a capital expenditure outlook.
Industry trends and dynamics
Medical cost trends remained elevated above historical industry levels, though broadly in line with CVS Health’s expectations; management expects an elevated trend environment to persist in 2027.
Management described Medicare as a high-trend environment, while reporting pockets of favorability and continued improvement supported by medical cost management, disciplined pricing, and other business actions.
Management said that roughly 2% of the population drives more than 50% of pharmacy spending, and that this spending is growing at a rate it views as unaffordable and unsustainable.
Prescription growth is expected to benefit from medical innovation and demographics, while the company characterized the retail pharmacy sector as economically resilient.
For 2027, Health Services faces a year-over-year decline in 340B and headwinds from a less robust selling season and health plan client membership attrition; CVS Health expects 340B to largely stabilize by year-end 2027.
Management said some expected 2027 Caremark membership declines reflect strategic decisions by health plan clients, including changes in Aetna’s PDP book, rather than the competitiveness of Caremark’s offerings.
Competitive landscape
Management described CVS Pharmacy as the best-run national pharmacy and highlighted its investments in technology, colleagues, and customer experience as differentiators.
Caremark cited its industry-leading cost of goods, customer focus, sophisticated capabilities, and pricing flexibility as elements of its value proposition.
Caremark achieved approximately $6 billion in gross new wins in the 2026 selling season, and management said it expects a robust 2028 sales season and new-business pipeline.
Management said CVS Specialty remains focused on driving competition and value for payer partners, and characterized specialty as a key cost-trend issue for customers.
CVS Health did not name specific competitors in the call.
Macroeconomic environment
The call did not provide a specific outlook on inflation, tariffs, recession, or other broad macroeconomic factors; management’s discussion of external cost pressures focused on elevated medical trends and pharmacy spending.
Growth opportunities and strategies
CVS Health announced its intention to separate into two publicly traded companies: a healthcare solutions company retaining Aetna, Caremark and Pharmacy Services, Specialty Pharmacy, Oak Street, and Signify Health; and CVS Pharmacy, comprising retail stores, mail order, MinuteClinic, and Health100.
The company expects the separation to be tax-free for U.S. federal income tax purposes and completed in the first half of 2028, subject to customary conditions; existing CVS Health shareholders are expected to own shares in both companies.
Management said the separation is intended to sharpen focus, enable tailored capital allocation, increase agility, and simplify operations and partnerships.
Management said commercial agreements will preserve selected relationships and products between the companies, while Health100 is intended to connect consumer engagement with health and pharmacy benefit information.
Health100 is described as an AI-native consumer engagement platform intended to serve as a front door to health and care and improve connectivity and interoperability.
CVS Pharmacy highlighted AI-supported pharmacy workflow for 85% of prescriptions, alongside investments in colleagues and omnichannel customer experience.
Management cited GLP-1 prescription growth of 23% in Q3 and said the company had made access more affordable and easier for patients.
CVS Pharmacy said its store footprint could support additional healthcare services and standardized community-based care.
CVS Health expects continued improvement in healthcare delivery and sees value in combining assets to support high-acuity populations and value-based care.
Financial Guidance and Outlook
2026 enterprise outlook: Adjusted EPS of at least $8.20, total revenue of at least $420 billion, adjusted operating income of at least $17.05 billion, and cash flow from operations of at least $15.5 billion.
2026 Health Care Benefits: Adjusted operating income of at least $5.4 billion; the full-year medical benefit ratio is expected in the lower half of the previously discussed 89.75% ± 25 basis points range.
2026 Pharmacy & Consumer Wellness: Adjusted operating income of at least $6.5 billion, representing nearly 8% growth year over year.
2027 enterprise outlook: Adjusted EPS of at least $8.65, reflecting approximately 13% growth from the adjusted 2026 baseline.
2027 Health Care Benefits: Management expects another year of meaningful margin improvement, driven largely by Medicare Advantage actions and disciplined underwriting and pricing; it also expects modest growth in the business.
2027 Health Services: Adjusted operating income is expected to be at least $7 billion; management characterized 2027 as trough earnings for the segment and expects a return to growth thereafter.
2027 Pharmacy & Consumer Wellness: Adjusted operating income is expected to grow at a low-single-digit rate from the 2026 guidance floor of $6.5 billion.
Management said CVS Health expects to reach the high end of its mid-teens adjusted EPS CAGR range through 2028.
The CFO said the 2027 EPS floor reflects the 2026 guidance increase carried forward and offsets dilution from share repurchases; he also indicated that the outlook does not assume a broader share-repurchase contribution.
Management said separation-related one-time and ongoing costs are expected to be manageable and that it intends to offset ongoing costs over time; it did not provide a specific cost estimate.
